RVT

Dexelvucitabine (RVT), a nucleoside reverse transcriptase inhibitor, is used potentially for the treatment of HIV infection.

Imeglimin (EMD 387008) is an orally available antidiabetic compound that enhances mitochondrial function, enhances insulin secretion, promotes β-cell proliferation and improves pancreatic β-cell survival in mice.

Relugolix (RVT-601) is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

Rodatristat ethyl (KAR5585) is a groundbreaking, orally active, and potent inhibitor of tryptophan hydroxylase 1 (TPH1) that significantly reduces 5-hydroxytryptamine (5-HT) levels and decreases pulmonary arterial hypertension (PAH) at low concentrations.

Intepirdine (GSK-742457) is a highly selective 5-HT6 receptor antagonist, used in trials studying the treatment of Alzheimer's Disease.

Lotamilast (RVT-501) is a phosphodiesterase 4 (PDE-4) inhibitor (IC50: 2.8 nM) potentially for the treatment of atopic dermatitis.

Batoclimab (RVT-1401) is a fully humanized immunoglobulin G1 (IgG1) monoclonal antibody that specifically targets the neonatal Fc receptor (FcRn) with high affinity for the IgG-binding site on FcRn, and by competitively binding to this site, Batoclimab effectively blocks FcRn-mediated recycling of immunoglobulin G (IgG), resulting in the enhanced degradation of IgG and subsequent reductions in circulating IgG levels, making it a candidate compound for research in autoimmune diseases such as myasthenia gravis and thyroid eye disease.

Afimkibart (PF06480605) is a humanised monoclonal antibody targeting TL1A (TNF-like Ligand 1A), which blocks TL1A-DR3 (death domain receptor 3) signalling on restrictive immune cells and fibroblasts. It can be used for inflammatory bowel disease and ulcerative colitis.